Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03166306 · ClinicalTrials.gov registry record · Phase 1
Angiogenic Imaging in Pulmonary Arterial Hypertension
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03166306 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 5 participants.
The verdict
NCT03166306, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Pulmonary arterial hypertension (PAH) is a disorder of elevated pulmonary vascular resistance characterized by progressive remodeling and obliteration of vessels of the distal pulmonary circulation. Outcomes in PAH could be improved with earlier diagnosis, and with the early deployment of therapies before irreversible changes have occurred. This study tests the sensitivity of positron emission tomography (PET)-CT scanning with \[89Zr\]-bevacizumab, a radioisotope-conjugated anti-VEGF antibody for detecting pulmonary vascular remodeling in PAH disease. This test could enable non-invasive diagnosis early in the course of the disease, and potentially improve outcomes in PAH,
Interventions
- DIAGNOSTIC_TEST PET-CT Imaging with [89Zr]-bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03166306
The ClinicalTrials.gov registry entry for NCT03166306 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PET-CT Imaging with [89Zr]-bevacizumab is the first listed.
NCT03166306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03166306 about?
NCT03166306 is a clinical study titled "Angiogenic Imaging in Pulmonary Arterial Hypertension". Pulmonary arterial hypertension (PAH) is a disorder of elevated pulmonary vascular resistance characterized by progressive remodeling and obliteration of vessels of the distal pulmonary circulation. Outcomes in PAH could be improved with earlier diagnosis, and with the early deployment of therapies ...
What is the current status of trial NCT03166306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-05-01. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03166306?
The interventions under investigation include: PET-CT Imaging with [89Zr]-bevacizumab (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03166306?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.